Exelixis, Inc. with ticker code (EXEL) now have 22 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $43.00 and $23.00 and has a mean target at $35.93. Given that the stocks previous close was at $32.96 and the analysts are correct then there would likely be a percentage uptick in value of 9.0%. There is a 50 day moving average of $34.75 while the 200 day moving average is $27.37. The company has a market cap of 9.40B. Currently the stock stands at: $32.93 USD
The potential market cap would be $10,250,216,468 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 21.25, revenue per share of $7.03 and a 12.81% return on assets.
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has four products, including its flagship molecule, cabozantinib, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company’s (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
